-
EP3730618
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3730618
| EP3730618 - RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 10.09.2021 Database last updated on 31.08.2024 | |
| Former | Request for examination was made Status updated on 28.09.2020 | Most recent event Tooltip | 10.09.2021 | Application deemed to be withdrawn | published on 13.10.2021 [2021/41] | Applicant(s) | For all designated states Alnylam Pharmaceuticals, Inc. 300 Third Street, 3rd Floor Cambridge, MA 02142 / US | [2020/44] | Inventor(s) | 01 /
KALLANTHOTTATHIL, Rajeev G. c/o Alnylam Pharmaceuticals, Inc. 300 Third Street, 3rd Floor Cambridge, MA 02142 / US | 02 /
ZIMMERMANN, Tracy c/o Alnylam Pharmaceuticals, Inc. 300 Third Street, 3rd Floor Cambridge, MA 02142 / US | 03 /
MANOHARAN, Muthiah c/o Alnylam Pharmaceuticals, Inc. 300 Third Street, 3rd Floor Cambridge, MA 02142 / US | 04 /
MAIER, Martin c/o Alnylam Pharmaceuticals, Inc. 300 Third Street, 3rd Floor Cambridge, MA 02142 / US | 05 /
KUCHIMANCHI, Satyanarayana c/o Alnylam Pharmaceuticals, Inc. 300 Third Street, 3rd Floor Cambridge, MA 02142 / US | 06 /
CHARISSE, Klaus c/o Alnylam Pharmaceuticals, Inc. 300 Third Street, 3rd Floor Cambridge, MA 02142 / US | [2020/44] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE | [2020/44] | Application number, filing date | 20164459.8 | 16.11.2012 | [2020/44] | Priority number, date | US201161561710P | 18.11.2011 Original published format: US 201161561710 P | US201261615618P | 26.03.2012 Original published format: US 201261615618 P | US201261680098P | 06.08.2012 Original published format: US 201261680098 P | [2020/44] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3730618 | Date: | 28.10.2020 | Language: | EN | [2020/44] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 17.09.2020 | Classification | IPC: | C12N15/113, A61K31/7125 | [2020/44] | CPC: |
C12N15/113 (EP,BR,IL,KR,RU,US);
C07H21/00 (BR,RU);
A61K31/7088 (BR,RU);
A61K31/7125 (EP,IL,KR,US);
A61K31/713 (EP,IL,KR,RU,US);
A61P25/00 (EP,IL);
A61P25/28 (EP,IL,KR);
A61P43/00 (EP,IL);
A61P5/14 (EP,IL);
C07H21/02 (EP,IL,KR,US);
C12N15/1136 (IL,US);
C12N2310/14 (EP,IL,KR,US);
C12N2310/315 (EP,IL,KR,US);
C12N2310/321 (IL,US);
C12N2310/322 (EP,IL,US);
C12N2310/343 (EP,IL,KR,US);
C12N2310/346 (EP,IL,KR,US);
C12N2310/351 (EP,IL,KR,US);
| C-Set: |
C12N2310/321, C12N2310/3521 (EP,US);
C12N2310/322, C12N2310/3533 (US,EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/44] | Extension states | BA | 30.03.2020 | ME | 30.03.2020 | Title | German: | RNAI-MITTEL, ZUSAMMENSETZUNGEN DARAUS UND VERFAHREN ZUR VERWENDUNG DAVON ZUR BEHANDLUNG VON MIT TRANSTHYRETIN (TTR) ASSOZIIERTEN KRANKHEITEN | [2020/44] | English: | RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES | [2020/44] | French: | AGENTS D'ARNI, COMPOSITIONS ET PROCÉDÉS D'UTILISATION CORRESPONDANTS POUR TRAITER DES MALADIES ASSOCIÉES À LA TRANSTHYRÉTINE (TTR) | [2020/44] | Examination procedure | 30.03.2020 | Examination requested [2020/44] | 29.04.2021 | Application deemed to be withdrawn, date of legal effect [2021/41] | 21.05.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2021/41] | Parent application(s) Tooltip | EP12850255.6 / EP2780353 | EP17184486.3 / EP3301177 | Divisional application(s) | EP21170872.2 | Fees paid | Renewal fee | 30.03.2020 | Renewal fee patent year 03 | 30.03.2020 | Renewal fee patent year 04 | 30.03.2020 | Renewal fee patent year 05 | 30.03.2020 | Renewal fee patent year 06 | 30.03.2020 | Renewal fee patent year 07 | 30.03.2020 | Renewal fee patent year 08 | 27.11.2020 | Renewal fee patent year 09 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2009002944 (ISIS PHARMACEUTICALS INC [US], et al); | [Y]WO2009134487 (ALNYLAM PHARMACEUTICALS INC [US], et al); | [Y]WO2010048228 (ALNYLAM PHARMACEUTICALS INC [US], et al); | [A]WO2010078536 (RXI PHARMACEUTICALS CORP [US], et al); | [Y]WO2011056883 (ALNYLAM PHARMACEUTICALS INC [US], et al); | [Y]WO2011123468 (ALNYLAM PHARMACEUTICALS INC [US], et al); | by applicant | US4683202 | US4897355 | WO9116024 | US5171678 | WO9324640 | WO9400569 | US5283185 | US5445934 | WO9637194 | US5677195 | US5744305 | US5770722 | WO9839359 | US5854033 | US5874219 | WO2007091269 | WO2007117686 | WO2009014887 | WO2009073809 | WO2010141511 | US7858769 | WO2011031520 | US8101348 | US20100615617 | US20160610186 | US20110610186 | US19480610397 | US20040916185 | US20040946873 | US20050115989 | US20070833934 | WO2007US80331 | US20070944227 | US20080047087 | WO2011US51597 | WO2012US43584 |